← Back to Search

Angiogenesis Inhibitor

Control group for Liver Cancer

Phase 3
Waitlist Available
Research Sponsored by Shanghai Junshi Bioscience Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 years
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This is a prospective, randomized, open-label, parallel-group, active controlled, multi-center phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab (hereafter referred to as JS001) combined with Bevacizumab versus Sorafenib as the first-line therapy for advanced HCC This study will enroll the patients with locally advanced or metastatic hepatocellular carcinoma who could not be radically cured and not receive any prior systemic therapy. The study will use PFS and OS as the co-primary endpoints, with approximately 280 patients planned to be enrolled.

Eligible Conditions
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall survival (OS)
Progression-free survival (PFS)
Secondary study objectives
ADA
Disease Control Rate (DCR)
DoR
+4 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Control groupActive Control1 Intervention
Sorafenib
Group II: Experimental groupActive Control1 Intervention
Toripalimab combined with Bevacizumab

Find a Location

Who is running the clinical trial?

Shanghai Junshi Bioscience Co., Ltd.Lead Sponsor
114 Previous Clinical Trials
27,442 Total Patients Enrolled
~64 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top